206 related articles for article (PubMed ID: 32123064)
21. Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer.
Muñoz-Moreno L; Schally AV; Prieto JC; Carmena MJ; Bajo AM
Prostate; 2018 Sep; 78(12):915-926. PubMed ID: 29748961
[TBL] [Abstract][Full Text] [Related]
22. Internalization and trafficking of the human and rat growth hormone-releasing hormone receptor.
Veyrat-Durebex C; Pomerleau L; Langlois D; Gaudreau P
J Cell Physiol; 2005 May; 203(2):335-44. PubMed ID: 15499571
[TBL] [Abstract][Full Text] [Related]
23. Impact of Axis of GHRH and GHRH Receptor on Cell Viability and Apoptosis of the Placental Choriocarcinoma Cell Line.
Liu AX; Zhang D; Zhu YM; Gao HJ; Jiang JY; Hu XL; Lv PP; Leung PC; Huang HF
Curr Mol Med; 2016; 16(3):299-311. PubMed ID: 26917260
[TBL] [Abstract][Full Text] [Related]
24. β-carotene attenuates lipopolysaccharide-induced inflammation via inhibition of the NF-κB, JAK2/STAT3 and JNK/p38 MAPK signaling pathways in macrophages.
Li R; Hong P; Zheng X
Anim Sci J; 2019 Jan; 90(1):140-148. PubMed ID: 30460722
[TBL] [Abstract][Full Text] [Related]
25. Growth hormone-releasing hormone promotes survival of cardiac myocytes in vitro and protects against ischaemia-reperfusion injury in rat heart.
Granata R; Trovato L; Gallo MP; Destefanis S; Settanni F; Scarlatti F; Brero A; Ramella R; Volante M; Isgaard J; Levi R; Papotti M; Alloatti G; Ghigo E
Cardiovasc Res; 2009 Jul; 83(2):303-12. PubMed ID: 19293247
[TBL] [Abstract][Full Text] [Related]
26. The effect of GHRH antagonists on human glioblastomas and their mechanism of action.
Pozsgai E; Schally AV; Zarandi M; Varga JL; Vidaurre I; Bellyei S
Int J Cancer; 2010 Nov; 127(10):2313-22. PubMed ID: 20162575
[TBL] [Abstract][Full Text] [Related]
27. The growth hormone-releasing hormone receptor: desensitisation following short-term agonist exposure.
Hansen BS; Gerlach LO; Hansen A; Foged C; Andersen PH
Pharmacol Toxicol; 2001 Feb; 88(2):81-8. PubMed ID: 11169166
[TBL] [Abstract][Full Text] [Related]
28. Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone.
Zhao L; Yano T; Osuga Y; Nakagawa S; Oishi H; Wada-Hiraike O; Tang X; Yano N; Kugu K; Schally AV; Taketani Y
Int J Oncol; 2008 Mar; 32(3):593-601. PubMed ID: 18292936
[TBL] [Abstract][Full Text] [Related]
29. Growth hormone-releasing hormone antagonist MIA-602 inhibits inflammation induced by SARS-CoV-2 spike protein and bacterial lipopolysaccharide synergism in macrophages and human peripheral blood mononuclear cells.
Granato G; Gesmundo I; Pedrolli F; Kasarla R; Begani L; Banfi D; Bruno S; Lopatina T; Brizzi MF; Cai R; Sha W; Ghigo E; Schally AV; Granata R
Front Immunol; 2023; 14():1231363. PubMed ID: 37649486
[TBL] [Abstract][Full Text] [Related]
30. Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway.
Guo J; Schally AV; Zarandi M; Varga J; Leung PC
Reprod Biol Endocrinol; 2010 May; 8():54. PubMed ID: 20509930
[TBL] [Abstract][Full Text] [Related]
31. Topical administration of diminazene aceturate decreases inflammation in endotoxin-induced uveitis.
Zheng C; Lei C; Chen Z; Zheng S; Yang H; Qiu Y; Lei B
Mol Vis; 2015; 21():403-11. PubMed ID: 25883526
[TBL] [Abstract][Full Text] [Related]
32. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
Heinrich E; Schally AV; Buchholz S; Rick FG; Halmos G; Mile M; Groot K; Hohla F; Zarandi M; Varga JL
Prostate; 2008 Dec; 68(16):1763-72. PubMed ID: 18729085
[TBL] [Abstract][Full Text] [Related]
33. Anti-inflammatory effect of angiotensin type 1 receptor antagonist on endotoxin-induced uveitis in rats.
Miyazaki A; Kitaichi N; Ohgami K; Iwata D; Jin XH; Iwabuchi K; Morohashi T; Ohno S; Onoé K
Graefes Arch Clin Exp Ophthalmol; 2008 May; 246(5):747-57. PubMed ID: 18087711
[TBL] [Abstract][Full Text] [Related]
34. Agonists of growth hormone-releasing hormone (GHRH) inhibit human experimental cancers in vivo by down-regulating receptors for GHRH.
Schally AV; Wang H; He J; Cai R; Sha W; Popovics P; Perez R; Vidaurre I; Zhang X
Proc Natl Acad Sci U S A; 2018 Nov; 115(47):12028-12033. PubMed ID: 30373845
[TBL] [Abstract][Full Text] [Related]
35. Sesquiterpene dimmer (DSF-27) inhibits the release of neuroinflammatory mediators from microglia by targeting spleen tyrosine kinase (Syk) and Janus kinase 2 (Jak2): Two major non-receptor tyrosine signaling proteins involved in inflammatory events.
Zeng KW; Wang S; Dong X; Jiang Y; Jin HW; Tu PF
Toxicol Appl Pharmacol; 2014 Mar; 275(3):244-56. PubMed ID: 24486434
[TBL] [Abstract][Full Text] [Related]
36. Resokaempferol-mediated anti-inflammatory effects on activated macrophages via the inhibition of JAK2/STAT3, NF-κB and JNK/p38 MAPK signaling pathways.
Yu Q; Zeng K; Ma X; Song F; Jiang Y; Tu P; Wang X
Int Immunopharmacol; 2016 Sep; 38():104-14. PubMed ID: 27261558
[TBL] [Abstract][Full Text] [Related]
37. Regulation of Vascular Calcification by Growth Hormone-Releasing Hormone and Its Agonists.
Shen J; Zhang N; Lin YN; Xiang P; Liu XB; Shan PF; Hu XY; Zhu W; Tang YL; Webster KA; Cai R; Schally AV; Wang J; Yu H
Circ Res; 2018 May; 122(10):1395-1408. PubMed ID: 29618597
[TBL] [Abstract][Full Text] [Related]
38. Fatty Acid Binding Protein-4 Silencing Inhibits Ferroptosis to Alleviate Lipopolysaccharide-induced Injury of Renal Tubular Epithelial Cells by Blocking Janus Kinase 2/Signal Transducer and Activator of Transcription 3 Signaling.
Xu S; Luo J; Wang Y; Chen X
J Physiol Investig; 2024 Jan; 67(1):47-56. PubMed ID: 38780272
[TBL] [Abstract][Full Text] [Related]
39. Curcumin attenuates inflammation and cell apoptosis through regulating NF-κB and JAK2/STAT3 signaling pathway against acute kidney injury.
Zhu H; Wang X; Wang X; Liu B; Yuan Y; Zuo X
Cell Cycle; 2020 Aug; 19(15):1941-1951. PubMed ID: 32615888
[TBL] [Abstract][Full Text] [Related]
40. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
Seitz S; Rick FG; Schally AV; Treszl A; Hohla F; Szalontay L; Zarandi M; Ortmann O; Engel JB; Buchholz S
Oncol Rep; 2013 Jul; 30(1):413-8. PubMed ID: 23624870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
